Ohtaki Y, Hida T, Hiramatsu K, Kanitani M, Ohshima T, Nomura M, Wakita H, Aburada M, Miyamoto K I
Faculty of Pharmaceutical Sciences, Hokuriku University, Tokyo, Japan.
Anticancer Res. 1996 Mar-Apr;16(2):751-5.
Although hepatocarcinogensis has been reported to be promoted by exogenous administration of bile acids, the relation of endogenous bile acids to hepatocarcinogenesis is not completely understood. This study investigates the relationship between serum concentration of bile acids, the appearance of preneoplastic change, glutathione S-transferase placental form (GST-P)-positive foci in the liver of male Donryu rats which had been fed 0.06% 3'-methyl-4-dimethylamino-azobenzene (3'-MeDAB), and the effects of gomisin A, previously reported to inhibit the tumor promotion process. During the feeding of 3'-MeDAB for 5 weeks, the concentrations of serum bile acids were found to have increased significantly to several times the levels found at the start of the experiment. The increase of serum bile acids, especially deoxycholic acid (DCA), and the appearance of preneoplastic lesions, the number and area of GST-P-positive foci in the liver, were significantly inhibited by simultaneous oral administration of gomisin A (30 mg/kg). When DCA (100 mg/kg) was orally administered after an initiation by 3'-MeDAB, serum bile acids and preneoplastic changes were significantly increased, these increases were inhibited by combined feeding of 0.03% gomisin A in the diet. There were good correlations between the serum concentration of DCA and the number of GST-P-positive foci in the liver in both experimental protocols. These results confirm that DCA is an endogenous risk factor for hepatocarcinogenesis and suggest that anti-promoter effect of gomisin A is based on improving metabolism of bile acids, including DCA.
虽然已有报道称外源性给予胆汁酸可促进肝癌发生,但内源性胆汁酸与肝癌发生之间的关系尚未完全明确。本研究调查了喂食0.06% 3'-甲基-4-二甲基氨基偶氮苯(3'-MeDAB)的雄性唐育大鼠肝脏中胆汁酸血清浓度、癌前病变的出现、谷胱甘肽S-转移酶胎盘型(GST-P)阳性灶与gomisin A(先前报道可抑制肿瘤促进过程)的作用之间的关系。在喂食3'-MeDAB的5周期间,发现血清胆汁酸浓度显著增加至实验开始时水平的数倍。同时口服gomisin A(30 mg/kg)可显著抑制血清胆汁酸的增加,尤其是脱氧胆酸(DCA),以及癌前病变的出现、肝脏中GST-P阳性灶的数量和面积。当在3'-MeDAB启动后口服DCA(100 mg/kg)时,血清胆汁酸和癌前病变显著增加,而在饮食中联合喂食0.03% gomisin A可抑制这些增加。在两个实验方案中,血清DCA浓度与肝脏中GST-P阳性灶的数量之间均存在良好的相关性。这些结果证实DCA是肝癌发生的内源性危险因素,并表明gomisin A的抗促进作用基于改善包括DCA在内的胆汁酸代谢。